What question did this study set out to answer?

To analyze drug survival rates of biologic treatments for psoriasis in Denmark using nationwide data.

Drug survival of biologic treatments for psoriasis and psoriatic arthritis in Denmark, 2018–23: a nationwide register–based cohort study

View Full Paper

Ask AI

Bookmark

Authors

Cohort study shows drug survival rates for biologics in psoriasis, indicating ustekinumab differs between conditions.

To analyze drug survival rates of biologic treatments for psoriasis in Denmark using nationwide data.
Nationwide register-based cohort study
Patients diagnosed with psoriasis and treated with biologics from 2018 to 2023
Stratified analyses by presence of psoriatic arthritis
Drug survival assessed using Kaplan–Meier curves
Discontinuation analyzed using Cox proportional hazards regression models
Infliximab had the highest 1-year drug survival at 49%
Ustekinumab had a 42% one-year survival rate
Bimekizumab had a 19% survival rate after 349 days
Ustekinumab showed greater persistence in psoriasis-only patients
Infliximab maintained lower risk of discontinuation compared to ustekinumab in PsA patients

Kim et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark